

August 01, 2025

To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.,
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001

To,
The Manager – Listing,
National Stock Exchange of India Ltd.,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Ref: Scrip Code: 543322

Ref: Scrip Name: ALIVUS

Dear Sirs,

Sub: Unaudited Financial Results for the First Quarter ended June 30, 2025

Pursuant to Regulations 30 and 33 of the SEBI LODR, 2015, we wish to inform you that the Board at its meeting held today approved the unaudited Financial Results for the First Quarter ended June 30, 2025.

The said meeting of the Board commenced at 5.00 p.m. and concluded at 5.50 p.m.

The copy of the said results, and Limited Review Report of the Auditor is enclosed herewith. These are also being made available on the website of the Company at www.alivus.com


You are requested to take the same on record.

Thanking You.

Yours faithfully,
For Alivus Life Sciences Limited
(formerly Glenmark Life Sciences Limited)



Rudalf Corriea
Company Secretary and Compliance Officer
Encl: As above



Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited)

Corporate Office:

4th Floor, OIA House, 470, Cardinal Gracious Road
Andheri (E), Mumbai 400 099, Maharashtra, India

Registered Office:

Plot No. 170-172, Chandramouli Industrial Estate
Mohol Bazarpeth, Solapur 413 213, India

T: +91 22 6829 7979 | CIN: L74900PN2011PLC139963 | E: complianceofficer@alivus.com | W: www.alivus.com



UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE, 2025

(₹ in Million, unless otherwise stated)

Sr. No.	Particulars	Quarter Ended			Year Ended
		30 Jun'25	31 Mar'25	30 Jun'24	31 Mar'25
		(Unaudited)	(Refer Note 5)	(Unaudited)	(Audited)
I	Income				
	Revenue from Operations	6,018.46	6,495.45	5,886.16	23,868.84
	Other Income	89.85	100.88	54.93	345.70
	Total Income	6,108.31	6,596.33	5,941.09	24,214.54
II	Expenses				
	Cost of Materials Consumed	2,689.75	2,804.54	2,463.55	10,535.02
	Changes in Inventories of Finished Goods and Work-in-Progress	14.10	21.42	414.34	273.50
	Employee Benefits Expense	615.77	667.22	568.44	2,516.96
	Finance Costs	12.51	12.60	3.53	24.14
	Depreciation and Amortisation Expense	170.64	159.70	143.87	606.09
	Other Expenses	975.73	1,017.95	844.98	3,717.52
	Total Expenses	4,478.50	4,683.43	4,438.71	17,673.23
III	Profit Before Tax (I-II)	1,629.81	1,912.90	1,502.38	6,541.31
IV	Tax Expenses				
	Current Tax	389.36	478.77	375.17	1,624.40
	Deferred Tax	25.10	15.45	12.38	60.64
	Total Tax Expenses	414.46	494.22	387.55	1,685.04
V	Profit for the Period / Year (III-IV)	1,215.35	1,418.68	1,114.83	4,856.27
VI	Other Comprehensive Income (OCI)				
	Items that will not be reclassified to profit or loss				
	(a) Re-measurement of the post-employment benefit obligation	(4.00)	(2.27)	(2.33)	(16.68)
	(b) Income tax relating to the above	0.96	0.76	0.59	4.20
	Total Other Comprehensive Income / (Loss)	(3.04)	(1.51)	(1.74)	(12.48)
VII	Total Comprehensive Income for the Period / Year (V+VI)	1,212.31	1,417.17	1,113.09	4,843.79
VIII	Earnings per equity share (Face Value of ₹ 2/- each) (Not Annualised except for the year ended 31st March)				
	(a) Basic (in ₹)	9.91	11.57	9.10	39.63
	(b) Diluted (in ₹)	9.88	11.55	9.08	39.52
IX	Paid up Equity Share Capital, Equity Shares of ₹ 2/- each	245.26	245.07	245.05	245.07
X	Other Equity excluding Revaluation Reserve	-	-	-	27,928.65

See accompanying notes to the Financial Results

Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited)


Corporate Office:

4th Floor, OIA House, 470, Cardinal Gracious Road
Andheri (E), Mumbai 400 099, Maharashtra, India

Registered Office:

Plot No. 170-172, Chandramouli Industrial Estate
Mohol Bazarpet, Solapur 413 213, India

T: +91 22 6829 7979 | CIN: L74900PN2011PLC139963 | E: complianceofficer@alivus.com | W: www.alivus.com




Notes:

1. The Financial Results have been prepared in accordance with Indian Accounting Standards ("Ind AS") prescribed under section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) including relevant circulars issued from time to time.
2. The above Financial Results were reviewed by the Audit Committee at their meeting held on August 1, 2025 and thereafter approved and taken on record by the Board of Directors at their meeting held on August 1, 2025. The results for the quarter ended June 30, 2025 have been subjected to Limited Review by Walker Chandio & Co. LLP, the Statutory Auditor of the company, who have expressed an unmodified conclusion on the said results.
3. The Company has identified only one segment i.e. Active Pharmaceutical Ingredient (API) as reporting segment based on the information reviewed by Chief Operating Decision Maker (CODM).
4. As at June 30, 2025, pursuant to Employee Stock Option Plan 2021, 6,52,831 options were outstanding, which upon exercise are convertible into equivalent number of equity shares.
5. The figures for the quarter ended 31st March 2025 are the balancing figures between the audited figures in respect of the full financial year and the unaudited year to date figures upto the third quarter of the relevant financial year.

For Alivus Life Sciences Limited
(formerly Glenmark Life Sciences Limited)



Yasir Rawjee
Managing Director & CEO
Mumbai, August 1, 2025



Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited)

Corporate Office:

4th Floor, OIA House, 470, Cardinal Gracious Road
Andheri (E), Mumbai 400 099, Maharashtra, India

Registered Office:

Plot No. 170-172, Chandramouli Industrial Estate
Mohol Bazarpet, Solapur 413 213, India

T: +91 22 6829 7979 | CIN: L74900PN2011PLC139963 | E: complianceofficer@alivus.com | W: www.alivus.com



Walker Chandiok & Co LLP

16th Floor, Tower III,
One International Center,
S B Marg, Prabhadevi (W),
Mumbai - 400 013
Maharashtra, India

T +91 22 6626 2600

Independent Auditor's Review Report on Unaudited Quarterly Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited)

1. We have reviewed the accompanying statement of unaudited financial results ('the Statement') of **Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited)** ('the Company') for the quarter ended **30 June 2025**, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited)
Independent Auditor's Review Report on Unaudited Quarterly Financial Results of the
Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure
Requirements) Regulations, 2015 (as amended)

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Walker Chandiok & Co LLP
Chartered Accountants
Firm Registration No: 001076N/N500013

YASHWANT Digitally signed by
MANGILAL YASHWANT
JAIN MANGILAL JAIN
Date: 2025.08.01
17:52:23 +05'30'

Yashwant M. Jain
Partner
Membership No. 118782
UDIN: **25118782BMOEMS4689**

Place: Mumbai
Date: 1 August 2025